Big pharma companies are ramping up the number of female bosses in Japan, with the percentage of women in managerial posts reaching 20% or more for seven out of 10 firms that disclosed their most recent data to Jiho by…
HOME > Special Interview on Long-Listed Products and Generic Drugs
Special Interview on Long-Listed Products and Generic Drugs
-
Astem Pres. Yoshimura Says Wholesalers Should Break Away from Dependence on Long-Listed Drugs
April 4, 2013
-
MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
-
CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
-
Japan Pharmaceutical Association Vice President Hirotsugu Miura Says that 70% Rule for New Generics Will Be Debatable in Future
March 15, 2013
-
Japan Health Insurance Association President Tsuyoshi Kobayashi Points Out that Price Competition Will Not Work If Prices Are Set Equally
March 12, 2013
-
Kyoto Medical Association Vice President Hideki Adachi Says Drug Makers Should Closely Verify NHI Prices and Development Costs of Each Drug
March 8, 2013
-
Shuji Shirakawa of Kenporen Says Long-Listed Product Price Cuts Irrelevant to New Drug Development Premium
February 28, 2013
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…